Accelerating Innovation at Leica Biosystems

Enhancing Cepheid's Long-Term Competitive Advantage Cepheid. ACCELERATING GROWTH INVESTMENTS RESULTS SINCE ACQUISITION >4K +2.5X >$0.5B ASSOCIATES INCREASE IN HIRED ANNUAL R&D SPEND CUMULATIVE CAPEX COVID-19 CONTRIBUTIONS 4-in-1 combo test: Flu A+ Flu B + RSV + COVID, 35min TTR • COVID-19 standalone test • Tests shipped: -20M (2020), ~50M (2021E) ANNUAL REVENUE & GLOBAL INSTALLED BASE >35K ~$3B >30K ~$2B >20K >10K -$1B $600M 2016 (At Acq.) 2019 2020 2021E RESULTS SINCE 2019: >50% INCREASE IN INSTALLED BASE +3X REVENUE INCREASE COVID-19 accelerated installed base growth, test menu & capacity DANAHER

View entire presentation